Vertex Pharmaceuticals to Participate in September Investor Conferences

Vertex Pharmaceuticals will participate in three investor conferences in September: the 2025 Wells Fargo Healthcare Conference, Morgan Stanley's 23rd Annual Global Healthcare Conference, and the Bank of America Global Healthcare Conference London. The conferences will feature management participation in fireside chats, and live webcasts of the events will be available on the company's website. Vertex is a global biotechnology company with approved therapies for cystic fibrosis, sickle cell disease, and other serious diseases.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will participate in three significant investor conferences in September, providing investors with opportunities to engage with the company's leadership. The engagements include fireside chats and live webcasts, accessible through the company's website.

Wells Fargo Healthcare Conference
Susie Lisa, Senior Vice President, Investor Relations, and Manisha Pai, Executive Director, Investor Relations, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 11:00 a.m. ET. This event is an opportunity for investors to gain insights into the company's strategic direction and financial performance.

Morgan Stanley 23rd Annual Global Healthcare Conference
Reshma Kewalramani, President and Chief Executive Officer, and Duncan McKechnie, Executive Vice President and Chief Commercial Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 11:30 a.m. ET. This conference is a platform for Vertex to discuss its innovations and growth prospects.

Bank of America Global Healthcare Conference London
Susie Lisa will also participate in a fireside chat at the Bank of America Global Healthcare Conference London on Tuesday, September 23, at 8:10 a.m. GMT. This event offers investors a chance to hear from Vertex's leadership about its global operations and future plans.

Vertex Pharmaceuticals is a global biotechnology company with a strong track record in developing transformative medicines for serious diseases. The company has approved therapies for cystic fibrosis, sickle cell disease, and transfusion-dependent beta thalassemia, among others. It continues to advance clinical and research programs in these areas and has a robust pipeline of investigational therapies across various modalities.

The company's leadership participation in these conferences underscores its commitment to transparency and investor engagement. For more information and to access the live webcasts, investors can visit the Vertex website.

References
[1] https://www.businesswire.com/news/home/20250820369043/en/Vertex-to-Participate-in-Upcoming-September-Investor-Conferences
[2] https://www.ainvest.com/news/top-3-growth-stocks-buy-august-eli-lilly-summit-therapeutics-vertex-pharmaceuticals-2508/